TELA Bio (TELA) Cost of Revenue (2018 - 2026)

TELA Bio's Cost of Revenue history runs 9 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 8.98% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $26.1 million, a 12.57% increase from a year earlier, with the FY2025 full-year figure at $25.6 million, up 13.92% from the prior year.
• Cost of Revenue eased to $6.4 million in Q1 2026 per TELA's latest filing, from $7.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $7.0 million in Q4 2025 and bottomed at $3.2 million in Q1 2022.
• The 5-year median for Cost of Revenue is $5.2 million (2024), against an average of $5.1 million.
• Across the five-year window, Cost of Revenue soared 57.54% in 2023 and gained 8.98% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $3.4 million in 2022, then surged by 57.54% to $5.3 million in 2023, then rose by 19.97% to $6.3 million in 2024, then rose by 10.83% to $7.0 million in 2025, then declined by 8.19% to $6.4 million in 2026.
• Per Business Quant, the three latest TELA Cost of Revenue figures stand at $6.4 million (Q1 2026), $7.0 million (Q4 2025), and $6.6 million (Q3 2025).